Tekmira on Track to Start Cancer Rx Trial Before Year-End; Cholesterol Drug Still On Hold | GenomeWeb

By Doug Macron

Tekmira Pharmaceuticals is on track to start enrolling patients in a phase I study of its solid tumor therapy TKM-PLK1, and is in talks with the National Cancer Institute over a possible collaboration on using the drug in liver cancer, the company's top official said this week.

Meanwhile, Tekmira continues to work on new formulations of its phase I hypercholesterolemia drug TKM-ApoB, which will not re-enter human testing this year as previously disclosed, President and CEO Mark Murray said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.